Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Mar. 31, 2011
REVENUES
Contract	$ 23,996	$ 61,294	$ 62,705	$ 472,849
Grant				846,768
Total revenues	23,996	61,294	62,705	1,319,617
Research and development	4,705,662	1,722,432	9,683,112	7,159,634
General and administrative	1,344,861	955,547	3,473,990	3,226,798
Total operating expenses	6,050,523	2,677,979	13,157,102	10,386,432
Loss from operations	(6,026,527)	(2,616,685)	(13,094,397)	(9,066,815)
Investment income	5,955	18,982	28,229	72,342
Interest expense	(1,830)	(1,974)	(6,650)	(5,607)
Increase in fair value of warrants		(1,257,691)		(1,257,691)
Gain on sale of securities		58,956		119,346
Gain (loss) on sale of supplies and equipment	1,700	(7,466)	4,700	(5,666)
Total other income (expense)	5,825	(1,189,193)	26,279	(1,077,276)
Loss before income taxes	(6,020,702)	(3,805,878)	(13,068,118)	(10,144,091)
Income tax benefit			1,068,233	637,391
NET LOSS	$ (6,020,702)	$ (3,805,878)	$ (11,999,885)	$ (9,506,700)
Basic and diluted net loss per common share	$ (0.17)	$ (0.17)	$ (0.34)	$ (0.65)
Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share	34,900,591	22,832,109	34,900,591	14,669,131